Sensus Healthcare (SRTS) to Release Earnings on Wednesday

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) is expected to be posting its quarterly earnings results after the market closes on Wednesday, February 5th. Analysts expect Sensus Healthcare to post earnings of $0.10 per share and revenue of $10.31 million for the quarter. Individual interested in registering for the company's earnings conference call can do so using this link.

Sensus Healthcare Stock Performance

Shares of SRTS traded up $1.36 during mid-day trading on Friday, hitting $8.23. 713,769 shares of the stock were exchanged, compared to its average volume of 187,031. The firm has a 50-day moving average of $7.50 and a two-hundred day moving average of $6.84. Sensus Healthcare has a 52-week low of $2.91 and a 52-week high of $9.33. The company has a market cap of $134.89 million, a PE ratio of 14.44 and a beta of 1.21.

Analyst Upgrades and Downgrades

SRTS has been the topic of a number of research reports. Lake Street Capital began coverage on shares of Sensus Healthcare in a report on Friday. They issued a "buy" rating and a $18.00 target price on the stock. Maxim Group lifted their target price on Sensus Healthcare from $12.00 to $14.00 and gave the stock a "buy" rating in a report on Friday, November 15th. Finally, HC Wainwright increased their price target on Sensus Healthcare from $10.00 to $11.00 and gave the company a "buy" rating in a report on Monday, November 18th.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.